Edition:
United Kingdom

Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS)

600521.SS on Shanghai Stock Exchange

20.25CNY
19 Sep 2018
Change (% chg)

¥0.93 (+4.81%)
Prev Close
¥19.32
Open
¥19.38
Day's High
¥20.50
Day's Low
¥19.21
Volume
11,293,658
Avg. Vol
12,897,842
52-wk High
¥32.83
52-wk Low
¥17.28

Latest Key Developments (Source: Significant Developments)

Zhejiang Huahai Pharma's Controlling Shareholder To Increase Holdings In The Company
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS CONTROLLING SHAREHOLDER PLANS TO INCREASE UP TO 5 MILLION SHARES IN THE COMPANY WITHIN SIX MONTHS.  Full Article

Zhejiang Huahai Pharmaceutical To Recall Valsartan-Containing Pharmaceutical Products From U.S. Consumers
Thursday, 19 Jul 2018 

July 19 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS IT DECIDES TO RECALL VALSARTAN-CONTAINING PHARMACEUTICAL PRODUCTS FROM CONSUMERS IN THE U.S. AND TO HALT ITS SUPPLY OF PRODUCTS TO THE U.S..SAYS ITS U.S. UNIT IS CONTACTING DISTRIBUTORS AND CUSTOMERS FOR PRODUCT RETURN.SAYS IT CANNOT ACCURATELY ESTIMATE THE LOSS CAUSED BY PRODUCT RECALL AT THIS STAGE, BUT WILL TRY TO MINIMIZE THE LOSSES.  Full Article

FDA Announces Voluntary Recall Of Several Medicines Containing Valsartan Following Detection Of An Impurity
Friday, 13 Jul 2018 

July 13 (Reuters) - Teva Pharmaceutical Industries Ltd ::FDA ANNOUNCES VOLUNTARY RECALL OF SEVERAL MEDICINES CONTAINING VALSARTAN FOLLOWING DETECTION OF AN IMPURITY.FDA SAYS VOLUNTARY RECALL DUE TO AN IMPURITY, N-NITROSODIMETHYLAMINE (NDMA), WHICH WAS FOUND IN THE RECALLED PRODUCTS.FDA SAYS PRESENCE OF NDMA IN RECALLED PRODUCTS WAS UNEXPECTED & IS THOUGHT TO BE RELATED TO CHANGES IN THE WAY THE ACTIVE SUBSTANCE WAS MANUFACTURED.FDA SAYS NOT ALL PRODUCTS CONTAINING VALSARTAN ARE BEING RECALLED.FDA SAYS TEVA PHARMACEUTICALS, MAJOR PHARMACEUTICALS, SOLCO HEALTHCARE RECALLING NON-EXPIRED PRODUCTS CONTAINING VALSARTAN SUPPLIED BY THIRD-PARTY.  Full Article

EMA Reviews Medicines Containing Valsartan From Zhejiang Huahai After Detection Of An Impurity
Thursday, 5 Jul 2018 

July 5 (Reuters) - European Medicines Agency (EMA): :EMA SAYS REVIEWING MEDICINES CONTAINING VALSARTAN FROM ZHEJIANG HUAHAI FOLLOWING DETECTION OF AN IMPURITY .EMA SAYS REVIEW WAS AFTER ZHEJIANG HUAHAI DETECTED IMPURITY, NDMA, IN VALSARTAN ACTIVE SUBSTANCE WHICH IS SUPPLIED TO SOME VALSARTAN MEDICINE MAKERS IN EU.  Full Article

Zhejiang Huahai Pharmaceutical Plans Share Private Placement, Scraps Convertible Bonds Issue
Friday, 25 May 2018 

May 25 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS IT PLANS TO RAISE UP TO 1.8 BILLION YUAN ($281.83 million) IN SHARE PRIVATE PLACEMENT.SAYS IT SCRAPS PLAN TO ISSUE CONVERTIBLE BONDS.  Full Article

Zhejiang Huahai Pharmaceutical passes FDA approval
Friday, 11 May 2018 

May 11(Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>:Says it received approval for its Clopidogrel hydrogen sulfate Tablets from U.S Food and Drug Administration.Company will be able to sell its Clopidogrel hydrogen sulfate Tablets in the United States after receiving the FDA approval.  Full Article

Zhejiang Huahai Pharmaceutical passes FDA approval
Wednesday, 18 Apr 2018 

April 18 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>:Says it received approval for its primary hypertension treatment drug from U.S Food and Drug Administration .  Full Article

Zhejiang Huahai Pharmaceutical's 2017 Net Profit Up 27.6 Pct Y/Y At 639.2 Mln Yuan
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS 2017 NET PROFIT UP 27.6 PERCENT Y/Y AT 639.2 MILLION YUAN ($101.61 million).  Full Article

Zhejiang Huahai Pharmaceutical says fire accident in unit's warehouse
Friday, 19 Jan 2018 

Jan 19(Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>:Says fire accident has occurred at a warehouse of co's Zhejiang-based wholly owned pharmaceutical unit, on Jan. 18.Says there were no casualties in the accident and the cause is under investigation.  Full Article

Zhejiang Huahai Pharmaceutical appoints Chen Baohua as chairman
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>:Says it appoints Chen Baohua as chairman .  Full Article

REFILE-UPDATE 3-Global health regulators find second toxin in common heart drug

FRANKFURT/BENGALURU, Sept 14 European and North American regulators have found a second toxin that may cause cancer in humans in a commonly used blood pressure drug made by Chinese firm Zhejiang Huahai Pharmaceutical Co Ltd.